Intended for healthcare professionals


AstraZeneca pays $520m fine for off label marketing

BMJ 2010; 340 doi: (Published 29 April 2010) Cite this as: BMJ 2010;340:c2380
  1. Janice Hopkins Tanne
  1. 1New York

    AstraZeneca agreed to pay a $520m (£340m; €391m) fine to settle allegations it had marketed the antipsychotic drug quetiapine fumarate (Seroquel) for unapproved off label uses, the US Department of Justice announced on 27 April.

    The drug was a bestseller for AstraZeneca in 2009, with sales of $4.9bn. Eric Holder, the US attorney general, took the unusual step of announcing the settlement at a news conference. He said that illegal acts by drug companies and false claims for government health programmes “can put the public health at risk, corrupt medical decisions by health care providers, and take …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription